Literature DB >> 20869649

Pathophysiology and management of heart failure in repaired congenital heart disease.

Paul F Kantor1, Andrew N Redington.   

Abstract

Up to 20% of all postoperative patients with repaired congenital heart disease later develop symptoms of heart failure, but slow disease progression makes patients difficult to study. The incidence is higher in the presence of lesions with a solitary or systemic right ventricle (RV). Several mechanisms cause the development of heart failure in this population, and the treatment options are not always aligned to conventional therapy for heart failure in a biventricular heart with cardiomyopathy. The pathogenesis and options for management of this complex problem in specific high-risk lesions are explored. Heart failure is commonly encountered in preoperative congenital heart disease and usually effectively dealt with by cardiac surgical or catheter-based interventions. Some lesions (single-ventricle physiology, tetralogy of Fallot, and systemic RV amongst others) are never completely repaired, and others may have persistent abnormal hemodynamic loading abnormalities; patients with these remain at risk of postoperative heart failure. Treatment is multifaceted and relies on focused surgical reintervention, timely medical therapy, and, occasionally, innovative measures, such as resynchronization therapy. The authors propose a construct whereby a primary underlying cause or substrate combined with additional remodeling stimuli results in the release of second messengers acting on classical heart failure signaling pathways. Together, these factors result in progressive heart failure in certain high-risk patients with congenital heart disease. Understanding this sequence leads to a logical application of treatments at the various stages of disease.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20869649     DOI: 10.1016/j.hfc.2010.06.002

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  5 in total

Review 1.  CSI position statement on management of heart failure in India.

Authors:  Santanu Guha; S Harikrishnan; Saumitra Ray; Rishi Sethi; S Ramakrishnan; Suvro Banerjee; V K Bahl; K C Goswami; Amal Kumar Banerjee; S Shanmugasundaram; P G Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U Mahajan; P P Mohanan; Sundeep Mishra; P K Deb; C Narasimhan; A K Pancholia; Ajay Sinha; Akshyaya Pradhan; R Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B C Srinivas; B P Chattopadhyay; B P Singh; J Balachandar; K R Balakrishnan; Brian Pinto; C N Manjunath; Charan P Lanjewar; Dharmendra Jain; Dipak Sarma; G Justin Paul; Geevar A Zachariah; H K Chopra; I B Vijayalakshmi; J A Tharakan; J J Dalal; J P S Sawhney; Jayanta Saha; Johann Christopher; K K Talwar; K Sarat Chandra; K Venugopal; Kajal Ganguly; M S Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V Deshpande; O P Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S Somasundaram; S N Routray; S S Iyengar; G Sanjay; Satyendra Tewari; Sengottuvelu G; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U C Samal; U Kaul; V K Chopra; V S Narain; Vimal Raj; Yash Lokhandwala
Journal:  Indian Heart J       Date:  2018-06-08

Review 2.  Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.

Authors:  Werner Budts; Jolien Roos-Hesselink; Tanja Rädle-Hurst; Andreas Eicken; Theresa A McDonagh; Ekaterini Lambrinou; Maria G Crespo-Leiro; Fiona Walker; Alexandra A Frogoudaki
Journal:  Eur Heart J       Date:  2016-01-18       Impact factor: 29.983

3.  [Adult patients with congenital heart disease].

Authors:  R G Grabitz; H Kaemmerer; F-W Mohr
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

Review 4.  Patient and Family Experience in a Multidisciplinary Clinic for Children With Single-Ventricle Heart Disease.

Authors:  Kelly R Wolfe; Sarah L Kelly; Deborah R Liptzin; Dania Brigham; Carey Rafferty; Adel K Younoszai; Michael V Di Maria
Journal:  J Patient Exp       Date:  2020-03-02

5.  Association of Digoxin With Interstage Mortality: Results From the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Use Dataset.

Authors:  Matthew E Oster; Michael Kelleman; Courtney McCracken; Richard G Ohye; William T Mahle
Journal:  J Am Heart Assoc       Date:  2016-01-13       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.